ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Now Rated “Hold” by Wall Street Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned an average rating of “Hold” from the seven ratings firms that are covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $99.60.

Several equities analysts recently commented on ANIP shares. Guggenheim reduced their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective on the stock. Canaccord Genuity Group decreased their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Finally, Oppenheimer began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price on the stock.

Insiders Place Their Bets

In other news, CFO Stephen P. Carey sold 2,850 shares of the company’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $73.00, for a total transaction of $208,050.00. Following the completion of the transaction, the chief financial officer directly owned 168,993 shares of the company’s stock, valued at approximately $12,336,489. This represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the stock in a transaction dated Tuesday, October 13th. The stock was sold at an average price of $73.59, for a total transaction of $36,795.00. Following the sale, the vice president owned 73,424 shares of the company’s stock, valued at approximately $5,403,272.16. This represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 25,012 shares of company stock worth $1,856,960. 8.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANIP. KBC Group NV bought a new stake in ANI Pharmaceuticals during the first quarter worth about $28,000. Versant Capital Management Inc boosted its stake in ANI Pharmaceuticals by 103.3% during the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 217 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of ANI Pharmaceuticals during the second quarter valued at $76,000. State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the second quarter valued at $86,000. Finally, GAMMA Investing LLC boosted its position in shares of ANI Pharmaceuticals by 13.4% during the third quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 211 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Down 1.0%

NASDAQ ANIP opened at $70.16 on Thursday. The stock’s 50-day simple moving average is $73.92 and its two-hundred day simple moving average is $78.01. ANI Pharmaceuticals has a twelve month low of $69.58 and a twelve month high of $97.00. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of 15.12, a PEG ratio of 2.28 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company’s revenue was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts forecast that ANI Pharmaceuticals will post 7.76 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.